All In Biotech

Drug Trial Radar · NCT00003490

Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma

Phase II to Treat Multiple Myeloma Patients With Cytoxan and Vincristine After Cycling Myeloma Cells With rHuGM-CSF

Last checked: Nov 19, 2026Latest source record: Dec 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 1998

Primary completion

Not stated

Study completion Aug 2003

Sponsor

Lead sponsor
The Cleveland ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 21, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. GM-CSF may make cancer cells more sensitive to the effects of chemotherapy. Combining more than one drug with GM-CSF may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of cyclophosphamide plus vincristine, following GM-CSF in treating patients with multiple myeloma that has not responded to previous treatment.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

  • sargramostimBiological

  • cyclophosphamideDrug

  • prednisoneDrug

  • vincristine sulfateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic Cancer Center

    Cleveland, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.